A clinical case of the retroperitoneal fibrosis (Ormond's disease) in rheumatology practice

Main Article Content

S.А. Trypilka
Ye.D. Yehudina


Retroperitoneal fibrosis (RPF) is a rare disease cha­racterized by the proliferation of inflammatory and fibrous tissue in the retroperitoneum. These masses are commonly loca­lized around the infrarenal part of the abdominal aorta and iliac arteries, often covering the ureters or other organs of the abdominal cavity; idiopathic diseases accounting for 70 % of cases. RPF may be associated with immunoglobulin G4 (IgG4), which accounts for two-thirds of idiopathic RPF cases. Secondary RPF may develop due to infections, malignant neoplasms, medication, retroperitoneal bleeding, or various other diseases. A cli­nical case of idiopathic RPF, probably associated with IgG4, was described in a patient who had undergone a symptomatic surgical treatment in an urological clinic and continued being trea­ted by a rheumatologist, given pathogenetic therapy (methylpredni­solone and mycophenolate mofetil) with a significant improvement. For rheumatologists, this pathology is of an undoubted clinical interest, since these changes are based on processes si­milar to those occurring in systemic diseases of the connective tissue, and the RPF is extremely rare, ranging from 0.1 to 1.3 cases per 100,000 patients per year. However, more often than not, such patients are referred to the doctors of ancillary specialties (urologists, nephrologists, surgeons, vascular surgeons). All of the abovementioned facts emphasize the importance of analyzing such a clinical case.

Article Details

How to Cite
Trypilka, S., and Y. Yehudina. “A Clinical Case of the Retroperitoneal Fibrosis (Ormond’s Disease) in Rheumatology Practice”. PAIN, JOINTS, SPINE, vol. 11, no. 1, Apr. 2021, pp. 42-49, doi:10.22141/2224-1507.11.1.2021.226909.
Clinical Case


Vaglio A, Maritati F. Idiopathic Retroperitoneal Fibrosis. J Am Soc Nephrol. 2016 Jul;27(7):1880-9. doi: 10.1681/ASN.2015101110. CrossRef PubMed

Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol. 1948 Jun;59(6):1072-9. doi: 10.1016/s0022-5347(17)69482-5. CrossRef PubMed

Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015 Apr 11;385(9976):1460-71. doi: 10.1016/S0140-6736(14)60720-0. CrossRef PubMed

van Bommel EFH, Jansen I, Hendriksz TR, Aarnoudse ALHJ. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). 2009 Jul;88(4):193-201. doi: 10.1097/MD.0b013e3181afc420. CrossRef PubMed

Goldoni M, Bonini S, Urban ML, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med. 2014 Aug 5;161(3):181-8. doi: 10.7326/M13-2648. CrossRef PubMed

Della-Torre E, Rigamonti E, Perugino C, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol. 2020 Mar;145(3):968-981.e14. doi: 10.1016/j.jaci.2019.07.004. CrossRef PubMed

Mattoo H, Mahajan VS, Maehara T, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol. 2016 Sep;138(3):825-838. doi: 10.1016/j.jaci.2015.12.1330. CrossRef PubMed

Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21-30. doi: 10.1007/s10165-011-0571-z. CrossRef PubMed

Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/ European League Against Rheumatism Classification Criteria for IgG4- Related Disease. Arthritis Rheumatol 2020;72(1):7-19. doi: 10.1002/art.41120. CrossRef PubMed

Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132. CrossRef PubMed

Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford). 2019 Jan 1;58(1):52-60. doi: 10.1093/rheumatology/key227. CrossRef PubMed

Wallace ZS. Kawano M, Saeki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: an update. Mod Rheumatol. 2019 Mar;29(2):231-239. doi: 10.1080/14397595.2018.1554321. CrossRef PubMed

Surcel C, Mirvald C, Pavelescu C, et al. Management of idiopathic retroperitoneal fibrosis from the urologist’s perspective Ther Adv Urol. 2015 Apr;7(2):85-99. doi: 10.1177/1756287214565637. CrossRef PubMed